Ulisse Biomed S.p.A.
UBM.MI · MIL
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.20 | 0.08 | -0.04 | -0.35 |
| FCF Yield | 2.25% | -8.59% | -1.66% | -4.95% |
| EV / EBITDA | 11.86 | -8.90 | -23.91 | -20.46 |
| Quality | ||||
| ROIC | 0.23% | -3.11% | -9.24% | -18.81% |
| Gross Margin | 1,659.08% | -108.98% | -2,078.93% | -5,427.17% |
| Cash Conversion Ratio | 0.43 | -0.16 | 0.63 | 0.37 |
| Growth | ||||
| Revenue 3-Year CAGR | 19.38% | 2.54% | 247.23% | 164.37% |
| Free Cash Flow Growth | – | – | – | – |
| Safety | ||||
| Net Debt / EBITDA | -1.00 | 0.32 | 1.63 | 3.83 |
| Interest Coverage | 240.25 | -109.48 | 0.00 | -6,961.94 |
| Efficiency | ||||
| Inventory Turnover | -8.97 | 0.39 | 0.55 | 4.52 |
| Cash Conversion Cycle | 932.58 | 164.87 | 4,146.97 | 4.12 |